286 - Baseline characteristics and treatment of US/UK pediatric patients with anemia of CKD on dialysis or not on dialysis treated with erythropoiesis-stimulating agents (ESA): a retrospective chart review

Poster Number: 286
Publication Number: 286.252

sally mountcastle, N/A, Moseley, VA, United States; Alice Rouleau, PPD, Part of Thermo Fisher Scientific, PARIS, Ile-de-France, France; Neil R. Brett, PPD, part of Thermo Fisher Scientific, Montreal, PQ, Canada; Justyna Amelio, GSK, London, England, United Kingdom; Thomas F. Hiemstra, GlacoSmithKline, Stevenage, England, United Kingdom; Juliet C. Roberts, GSK, Stevenage, England, United Kingdom; Kathy H. Fraeman, Other, Olney, MD, United States; Jake Hunnicutt, GSK, Collegeville, PA, United States; Veronique Page, Thermo Fisher, Montreal, PQ, Canada; Susanna Cuadripani, GSK, Stevenage, England, United Kingdom; David Webb, GSK, London, England, United Kingdom; Amrit Kaur, Royal Manchester Children's Hospital, Manchester, England, United Kingdom; Rukshana Shroff, UCL Great Ormond Street Institute of Child Health, London, England, United Kingdom; Anna Richards, GSK, Brentford, England, United Kingdom; Keele Wurst, GSK, Research Triangle, NC, United States

Background: Anemia occurs commonly in pediatrc CKD and is associated with adverse clinical outcomes.

Objective: We assessed the completeness and availability of patient characteristics and treatment data in a pediatric population with anemia of CKD (dialysis/non-dialysis [ND]) treated with ESA.

Design/Methods: Retrospective chart review conducted 1 Nov–20 Dec 2021 in US/UK patients aged < 18 yrs at index date who received ESA for anemia of CKD. Eligibility period was 1 Jan 2017–31 Dec 2018. Index date was defined as 1 Jan 2017 if a patient was already receiving ESA treatment at the start of the eligibility period (prevalent user), or date of ESA treatment initiation within the eligibility period (new user). Data was collected using an electronic case report form from index date until earliest of: permanent ESA discontinuation, 52 wks after index date (for those without renal transplant), 52 wks from the receipt of renal transplant (for those transplanted), loss to follow-up, or death. Chart reviews were completed by treating physicians from a panel (US) and treating physicians/authorised staff (UK). Descriptive statistics were used to report the data.

Results: Of the 50 patients included, 14 (28.0%) were from the US and 36 (72.0%) from the UK; the median age was 9.0 yrs (min/max: < 1/15; IQR: 4.0– 11.0) and 22 (44.0%) were female. The most common CKD etiologies were congenital abnormalities of the kidney/urinary tract (n=14, 28.0%) and obstructive nephropathy (n=7, 14.0%). The overall mean (SD) duration since CKD diagnosis was 43.3 (48.9) months. The most common comorbidities at index were hypertension (n=15, 30.0%), neurocognitive impairment (n=11, 22.0%) and growth abnormalities (n=10, 20.0%). Baseline CKD stage was recorded for 49 patients as: stage 3 in 9 (18.4%), stage 4 in 11 (22.4%), stage 5 in 12 (24.5%) and end-stage in 17 (34.7%) with 23 of 50 patients (46.0%) receiving dialysis (15 hemodialysis, 8 peritoneal dialysis). Eight (16.0%) had a renal transplant post-index. Mean (SD) hemoglobin level at index was 9.5 (2.0) g/dL in those on dialysis and 10.5 (1.8) g/dL in those not on dialysis. At index, 23 (46.0%) were prevalent ESA users and 27 (54.0%) were new users. A proportion of patients were receiving iron treatment during index ESA line (n=28, 56.0%): oral iron, n=18 (64.3%) with 13 (72.2%) of these ND patients; intravenous iron, n=10 (35.7%) with 2 (20.0%) of these patients ND.

Conclusion(s): This study provides important insights on characteristics and treatments of a pediatric population with anemia of CKD within US/UK.

Funding: GSK (Study 213734)